In vivo involvement of heparan sulfate proteoglycan in the bioavailability, internalization, and catabolism of exogenous basic fibroblast growth factor

Molecular Pharmacology

Volumn 55, Issue 1, 1999, Pages 74-82

  Colin, Sylvie ^a,d   Jeanny, Jean Claude ^b   Mascarelli, Frederic ^b   Vienet, Raymond ^c   Al Mahmood, Salman ^d   Courtois, Yves ^b   Labarre, Jean ^a  

^a CEA SACLAY   (France)

^b BICHAT HOSPITAL   (France)

^c Institut National de la Recherche Agronomique   (France)

^d Université Paris Descartes   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEOHEPARAN SULFATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG POTENTIATION; ELECTROPHORESIS; EXTRACELLULAR MATRIX; INTERNALIZATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT;

EID: 0032923918     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.55.1.74     Document Type: Article

References (39)

1. Abboud HE (1993) Growth factors in glomerulonephritis. Kidney Int 43:252-267.
2. Bikfalvi A, Klein S, Pintucci G, Quarto N, Mignatti P, and Rifkin DB (1995) Differential modulation of cell phenotype by different molecular weight forms of basic fibroblast growth factor: Possible intracellular signaling by the high molecular weight forms. J Cell Biol 129:233-243.
3. Burgess WH and Maciag T (1989) The heparin-binding (fibroblast) growth factor family of proteins. Annu Rev Biochem 58:575-606.
4. Cobb MH, Boulton TG and Robbins DJ (1991) Extracellular signal-regulated kinases: ERKs in progress. Cell Regul 2:965-978.
5. 125I recombinant fibroblast growth factor 2. Eur J Biochem 249:473-480.
6. Coughlin SR, Barr PJ, Cousens LS, Fretto LJ and Williams LT (1988) Acidic and basic fibroblast growth factors stimulate tyrosine kinase activity in vivo. J Biol Chem 263:988-993.
7. Denekamp J (1984) Vascular endothelium as the vulnerable element in tumours. Acta Radiol Oncol 23:217-225.
8. Flaumenhalft R, Moscatelli D, Saksela O and Rifkin DB (1989) Role of ECM in the action of basic fibroblast growth factor: Matrix as a source of growth factor for long-term stimulation of plasminogen activator production and DNA synthesis. J Cell Physiol 140:75-81.
9. Floege J, Eng E, Volkard L, Alpers CE, Young BA, Reidy MA and Johnson RJ (1992) Rat glomerular mesangial cells synthesize basic fibroblast growth factor: Release, upregulated synthesis, and mitogenicity in mesangial proliferative glomerulonephritis. J Clin Invest 90:2362-2369.
10. Folkman F and Klagsbrun M (1987) Angiogenic factors. Science 235:442-447.
11. Givol D and Yayon A (1992) Complexity of FGF receptors: Genetic basis for structural diversity and functional specificity. FASEB J 6:3362-3369.
12. Gonzalez AM, Buscaglia M, Ong M and Baird A (1990) Distribution of basic fibroblast growth factor in the 18-day rat fetus: Localization in the basement membranes of diverse tissues. J Cell Biol 110:753-765.
13. Guillonneau X, Tassin J, Berrou E, Bryckaert M, Courtois Y and Mascarelli F (1996) In vitro changes in plasma membrane heparin sulfate proteoglycans and in perlecan expression participate in the regulation of fibroblast growth factor 2 mitogenic activity. J Cell Physiol 166:170-187.
14. Hanneken A, Maher PA and Baird A (1995) High affinity immunoreactive FGF receptors in the extracellular matrix of vascular endothelial cells: Implications for the modulation of FGF2. J Cell Biol 128:1221-1228.
15. Hanneken A, Wenbin Y, Ling N and Baird A (1994) Identification of soluble forms of the fibroblast growth factor receptor in blood. Proc Natl Acad Sci USA 91:9170-9174.
16. Hicks D, Bugra K, Faucheux B, Jeanny JC, Laurent M, Malecaze F, Mascarelli F, Raulais D, Cohen SY and Courtois Y (1991) Fibroblast growth factors in the retina. Progr Retinal Res 11:333-374.
17. Hondermarck H, Courty J, Boilly B and Thomas D (1990) Distribution of intravenously administered acidic and basic fibroblast growth factors in the mouse. Experentia 46:973-974.
18. Jaye M, Schlessinger J and Dionne CA (1992) Fibroblast growth factor receptor tyrosine kinases: Molecular analysis and signal transduction. Biochem Biophys Acta 1135:185-199.
19. Kanwar YS and Farquar MG (1979) Presence of heparan sulfate in glomerular basement membrane. Proc Natl Acad Sci USA 76:1303-1307.
20. Kanwar YS, Liu ZZ, Kashihara N and Wallner EI (1991) Current status of the structural and functional basis of glomerular filtration and proteinuria. Semin Nephrol 11:390-413.
21. Klagsbrun M and Edelman ER (1989) Biological and biochemical properties of fibroblast growth factors: Implications for the pathogenesis of atherosclerosis. Arteriosclerosis 9:269-278.
22. Linhardt RJ, Turnbull JE, Wang HM, Loganathan D and Gallagher JT (1990) Examination of the substrate specificity of heparin and heparan sulfate lyases. Biochemistry 29:2611-2617.
23. Liu J and Walsh CT (1990) Peptidyl-propyl cis-trans-isomerase from Escherichia coli: A periplasmic homolog of cyclophilin that is not inhibited by cyclosporin A. Proc Natl Acad USA 87:4028-4032.
24. Lobb RR (1988) Clinical applications of heparin-binding growth factors. Eur J Clin Invest 18:321-336.
25. Malecaze F, Mascarelli F, Bugra K, Fuhrmann G, Courtois Y and Hicks D (1993) Fibroblast growth factor receptor deficiency in dystrophic retinal pigmented epithelium. J Cell Physiol 154:631-642.
26. Moscatelli D (1987) High and low affinity-binding sites for basic fibroblast growth factor on cultured cells: Absence of a role for low affinity binding in the stimulation of plasminogen activator production by bovine capillary endothelial cells. J Cell Physiol 131:123-130.
27. Moscatelli D (1988) Metabolism of receptor-bound and matrix-bound basic fibroblast growth factor by bovine capillary endothelial cells. J Cell Biol 107:753-759.
28. Reiland J and Rapraeger AC (1993) Heparan sulfate proteoglycan and FGF receptor target basic FGF to different intracellular destinations. J Cell Sci 105:1085-1093.
29. Roghani M, Mansukhani A, Dell'Era P, Bellosta P, Basilico C, Rifkin DB and Moscatelli D (1994) Heparin increases the affinity of basic fibroblast growth factor for its receptor but is not required for binding. J Biol Chem 269:3976-3984.
30. Roghani M and Moscatelli D (1992) Basic fibroblast growth factor is internalized through both receptor-mediated and heparan sulfate-mediated mechanisms. J Biol Chem 267:22156-22162.
31. Saksela O, Moscatelli D, Sommer A and Rifkin DB (1988) Endothelial cell-derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation. J Cell Biol 107:743-751.
32. Savona C, Chambaz EM and Feige JJ (1991) Proteoheparan sulfates contribute to the binding of basic FGF to its high-affinity receptors on bovine adrenocortical cells. Growth Factors 5:273-282.
33. Sommer A and Rifkin DB (1989) Interaction of heparin with human basic fibroblast growth factor: Protection of the angiogenic protein from proteolytic degradation by a glycosaminoglycan. J Cell Physiol 138:215-220.
34. Tumova S and Bame KJ (1997) The interaction between basic fibroblast growth factor and heparan sulfate can prevent the in vitro degradation of the glycosaminoglycan by Chinese hamster ovary cell heparanases. J Biol Chem 272:9078-9085.
35. Vlodavsky I, Folkman J, Sullivan R, Fridman R, Ishai-Michaeli R, Sasse J and Klagsburn M (1987) Endothelial cell-derived basic fibroblast growth factor: Synthesis and deposition into subendothelial extracellular matrix. Proc Natl Acad Sci USA 84:2292-2296.
36. Whalen GF, Shing Y and Folkman J (1989) The fate of intravenously administrated bFGF and the effect of heparin. Growth Factors 1:157-164.
37. Wilson EL, Rifkin DB, Kelly F, Hannocks MJ and Gabrilove JL (1991) Basic fibroblast growth factor stimulates myelopoeisis in long-term human bone marrow cultures. Blood 77:954-960.
38. Yayon A, Klagsbrun M, Esko JD, Leder P and Ornitz DM (1991) Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high-affinity receptor. Cell 64:841-848.
39. 1 after topical and intravenous administration in male rats. Pharm Res 11:213-220.